Jan. 23 at 10:40 AM
$HCWB Maxim has pt of
$8>>>this is how you do it. Get in early
HCW9302 (IL-2 fusion for selective Treg expansion): Phase 1 first-in-human trial initiated in November 2025 for moderate-to-severe alopecia areata (first patient dosed at Ohio State University; ongoing multi-center study).
HCW9218 (bifunctional molecule): Completed Phase 1 in solid tumors; Phase 1b/2 in pancreatic cancer.
Preclinical/early assets: Tetra-valent checkpoint inhibitors (e.g., HCW11-040), T-cell engagers for solid tumors, and others (data presented at SITC 2025); some licensed (e.g., to WY Biotech, Wugen).
The company has partnerships for cell therapy and co-development but no approved products or significant revenue (~
$2.57M in 2024, down YoY; ongoing net losses ~
$30M annually).
